Highlights NeurAxis, Inc.

Equities

NRXS

US64134X2018

Market Closed - Nyse Other stock markets 21:10:00 14/06/2024 BST			5-day change	1st Jan Change
2.97 ^USD	-1.00%		-0.67%	+11.24%

06-07	NeurAxis Submits Application to FDA to Expand IB-Stim Label	MT
05-22	Earnings Flash (NRXS) NEURAXIS Posts Q1 Revenue $646,635	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NeurAxis Submits Application to FDA to Expand IB-Stim Label	06-07	MT
Earnings Flash (NRXS) NEURAXIS Posts Q1 Revenue $646,635	05-22	MT
Neuraxis, Inc. Provides Earnings Guidance for Late 2024 and 2025	05-22	CI
NeurAxis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-20	CI
NeurAxis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-09	CI
NeurAxis, Inc. Provides Revenue Guidance in Late 2024 and into 2025	04-09	CI
NeurAxis, Inc. Announces IB-Stim Results from A Large, Pediatric, Multi-Center Registry	03-27	CI
NeurAxis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-20	CI
NeurAxis, Inc. Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device	11-08	CI
NeurAxis, Inc. Announces Results of Comparative Study of IB-Stim and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders	26/09/23	CI
Earnings Flash (NRXS) NEURAXIS Posts Q2 Revenue $646,000	21/09/23	MT
NeurAxis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	21/09/23	CI
NeurAxis, Inc. Announces Publication of Prospective Study Showing IB-Stim Improves Quality of Life of Adolescents with IBS	12/09/23	CI
Neuraxis, Inc. Highlights Pediatric Post-Concussion Clinical Study	29/08/23	CI
NeurAxis, Inc. has completed an IPO in the amount of $6.592002 million.	08/08/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW